
AbbVie (ABBV) Stock Forecast & Price Target
AbbVie (ABBV) Analyst Ratings
Bulls say
AbbVie has reaffirmed a strong long-term sales outlook with guidance indicating a high single-digit compound annual growth rate (CAGR) from 2024 to 2029, backed by anticipated robust sales of Skyrizi and Rinvoq, which are projected to exceed $20 billion and $11 billion, respectively, by 2027. The company's fourth quarter of 2024 delivered sales of $15.1 billion, exceeding expectations primarily due to the success of key products in its immunology portfolio, illustrating its solid market position. Additionally, AbbVie is maintaining its reported EPS guidance for 2025 at $12.12–$12.32, reflecting confidence in financial performance amidst ongoing investments in research and development.
Bears say
AbbVie faces significant downside risks that could adversely affect its stock performance, primarily due to disappointing commercial execution on key assets such as Skyrizi, Rinvoq, and Botox, coupled with potential regulatory setbacks and clinical data failures. The company's reliance on discretionary consumer spending for its aesthetics business introduces vulnerability, especially in light of ongoing macroeconomic challenges that could hinder overall sales growth. Additionally, heightened competitive pressures, particularly with the impending erosion of Humira’s market share due to biosimilar entries and stagnant market penetration with Rinvoq and Skyrizi, further contribute to a negative outlook for AbbVie’s future financial performance.
This aggregate rating is based on analysts' research of AbbVie and is not a guaranteed prediction by Public.com or investment advice.
AbbVie (ABBV) Analyst Forecast & Price Prediction
Start investing in AbbVie (ABBV)
Order type
Buy in
Order amount
Est. shares
0 shares